Stock Ratings / Health Care / MNKD / earnings

HROW (71) SPTX (56) CTY (61) AVLN (49) ⌘ Pro Terminal →

MannKind Corporation (MNKD) Next Earnings Date & Expected ±11.1% Move

$3.50 +2.04% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.51

MannKind Corporation (MNKD) carries a Roarable Rating of C (Hold) with 63/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 63/100 (C) historically posted market-perform odds over rolling 90-day windows (+0.9% avg 90D alpha vs SPY) →

ROARABLE C • HOLD / WATCH Cap $1.13B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.51 (+0.18%)🧬 Disciplined Float (-0.32% YoY Shares)⚙️ Cash Engine: 14/20 (B-) • 3.9% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 63/100 (C) historically posted market-perform odds over rolling 90-day windows (+0.9% avg 90D alpha vs SPY • 54.8% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE+2.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MNKD)Realized 20D OHLCV Swing Band: ±11.1%

Deterministic 5-Pillar Attribution (63/100 Composite)

🔍 WHY MNKD SCORES 63/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+14/20 pts (22% of score)

SEC XBRL FY 2025 (10-K): 3.9% FCF Margin ($13.7M FCF) & 92.3% Gross Margin

▲ #2 Bullish Driver: Macro Regime Fit+13/20 pts (21% of score)

FRED Regime × Technicals: 30% of 52W Range • RSI-14 at 55.6 (BULLISH MOMENTUM)

▼ #1 Drag / Risk Factor: Whale & Options Positioning11/20 pts (-9 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-9 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C$3.29-7.6% Next Q

Q2 (-2Q)

Grade C$3.04+4.9% Next Q

Q3 (-1Q)

Grade C$3.19+9.7% Next Q

Current

Grade C$3.50+0.9% Hist 90D α

Trajectory: C (55) → C (63)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the MNKD Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 63/100 (C) score, MNKD faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Disciplined Float (-0.32% YoY Shares) — any gross margin slip below 89.8% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($3.58) or 200D SMA ($3.73) invalidates the momentum regime and cuts Target Base ($3.58) toward Bear Floor ($2.79).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $MNKD• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “MNKD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 63%NO 37%Trade / Inspect Odds →

NEXT EST. WINDOW: Dec 30, 2026 (~58 DAYS)

Historical OHLCV Volatility ±11.1% Swing Band

±$0.39 Expected Swing

MODEL EARNINGS SETUP GAUGE

MNKD Quantitative Pre-Earnings Setup: 63/100

Trailing EPS: $4.25 • YoY Revenue Growth: 22.2%

Model Bullish Setup (63/100)Model Risk Weight (37/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$349.0M	$5.9M	$13.7M	92.3%
FY 2024	2024-12-31	$285.5M	$27.6M	$32.8M	93.9%
FY 2023	2023-12-31	$199.0M	-$11.9M	$34.1M	92%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating MNKD & AI Leaders Without Chasing Tops

✓Institutional whale strikes & implied earnings move audit on MNKD
✓How disciplined traders manage risk using pre-published trigger & invalidation levels
✓Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

MNKD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +23.67%▼ DESCENDING CHANNEL

2026-10-30O $3.50H $3.57L $3.45C $3.50VOL 2.01M

RES: $4.21SUP: $2.73SMA50: $3.58SMA200: $3.73

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MNKD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 MNKD Butterfly Map → + Track MNKD →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

23.7%/yr Implied 5Y Growth

vs. +22.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on MNKD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for MNKD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for MNKD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MNKD)

Health Care Rank #158 of 1016 ⚔️ HROW vs MNKD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (MNKD vs. HROW, SPTX, CTY, AVLN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, MannKind Corporation (MNKD) ranks #158 by composite RQD confidence (63/100, grade C) and #348 by equity capitalization ($1.13B). Within this direct 5-issuer industry benchmark cohort, MNKD leads on earnings valuation at N/A trailing P/E, while MNKD leads on capital efficiency and profitability with 54.5% ROIC and 92.3% gross margin. HROW currently holds the highest overall quantitative score in the immediate peer group at 71/100 (B-) compared with MNKD at 63/100 (C).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
MNKD ACTIVE MannKind Corporation	C	63/100	—	92.3%	54.5%	+2.04%	$1.13B	Benchmark Subject
HROW Harrow Inc.	B-	71/100	—	75.1%	42.9%	+2.04%	$1.12B	/hrow-vs-mnkd →
SPTX Seaport Therapeutics Inc.	D+	56/100	—	—	—	+3.53%	$1.13B	/sptx-vs-mnkd →
CTY City Therapeutics Inc.	C-	61/100	—	—	—	+2.26%	$1.11B	/cty-vs-mnkd →
AVLN Avalyn Pharma Inc.	D	49/100	—	—	—	-0.12%	$1.14B	/avln-vs-mnkd →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000899460

In its most recent audited fiscal period (FY2025, filed 2025-12-31), MannKind Corporation (MNKD) reported GAAP revenue of $349.0M (+22.2% vs. FY2024 revenue of $285.5M , and +75.4% cumulative change since FY2023) , GAAP net income of $5.9M, operating cash flow of $18.3M, and free cash flow of $13.7M (-58.3% YoY). On the balance sheet, MNKD closed FY2025 with $792.2M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$349.0M	$5.9M	$18.3M	$13.7M	$792.2M	—
FY2024 (FY)	2024-12-31	$285.5M	$27.6M	$42.5M	$32.8M	$393.8M	—
FY2023 (FY)	2023-12-31	$199.0M	-$11.9M	$34.1M	$34.1M	—	—

3. MNKD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MNKD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, MannKind Corporation (NASDAQ: MNKD) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 63/100 at a spot price of $3.50 (+2.04% 1D, market cap $1.13B). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 13/20. Across 1016 tracked Health Care issuers, MNKD ranks #158 in composite RQD confidence.

How does MNKD compare to HROW and SPTX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MNKD carries a Roarable C (63/100 RQD), trailing P/E of N/A, gross margin of 92.3%, and ROIC of 54.5%. By comparison, HROW (Harrow Inc.) holds a B- grade (71/100 RQD, P/E N/A, ROIC 42.9%, cap $1.12B) and SPTX (Seaport Therapeutics Inc.) posts a D+ grade (56/100 RQD, P/E N/A, ROIC —, cap $1.13B). Among the 5-stock peer group, MNKD leads on earnings multiple (N/A) while MNKD leads on capital efficiency (54.5% ROIC).

What are the biggest fundamental strengths and SEC risk factors for MNKD?

Per MNKD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000899460), MannKind Corporation generated $349.0M in revenue (+22.2% YoY), $5.9M in net income, and $13.7M in free cash flow against $792.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is MNKD trading relative to its 50-day, 200-day, and 52-week technical levels?

MNKD last traded at $3.50 (+2.04% on volume of 2,276,272 shares), positioning the stock -2.23% below its 50-day simple moving average ($3.58) and -6.17% below its 200-day simple moving average ($3.73). Across its 52-week range of $2.23 to $6.51, MNKD sits at the 29.7% percentile with a 14-day RSI of 55.6 (BULLISH MOMENTUM) and an implied next-earnings move of ±11.1% ($3.11 to $3.89).

MNKD Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is MNKD's next earnings date?

Based on SEC filing cadence, MannKind Corporation (MNKD)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is MNKD stock expected to move on earnings?

Volatility modeling currently projects a ±11.1% event move for MNKD, spanning a range between $3.11 and $3.89.

Direct Sub-Reports: MNKD RQD Cockpit MNKD 12M Forecast MNKD Earnings & Move MNKD Dividends & DRIP MNKD Insiders & 13F MNKD Whale Options MNKD Profit Sankey MNKD News & Why